Overview

Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first‑in‑class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to treat patients across dozens of severe autoimmune diseases. We are building a new kind of biotech company, one that maintains its roots as a science‑based start‑up and pushes our commitment to innovate across all corners of our business. As part of our expansion in Brazil, we are seeking a Key Account Manager (KAM) to support the launch and establishment of our innovative therapies in areas of high unmet medical need. This territory is located in Curitiba. This is a highly visible, field‑based role with the opportunity to contribute to improving patient outcomes by supporting the integration of innovative t...